Cargando…

Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study

AIM: Methamphetamine (MA) abuse and dependence are increasing worldwide and are commonly associated with cognitive deficits. Some studies indicate that such impairments can improve if users become abstinent, but overall results remain inconclusive. Hence, we have performed a longitudinal case-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernhardt, Nadine, Petzold, Johannes, Groß, Cornelius, Scheck, Anna, Pooseh, Shakoor, Mayer-Pelinski, René, Zimmermann, Ulrich S., Smolka, Michael N., Pilhatsch, Maximilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343893/
https://www.ncbi.nlm.nih.gov/pubmed/32714215
http://dx.doi.org/10.3389/fpsyt.2020.00581
_version_ 1783555844188667904
author Bernhardt, Nadine
Petzold, Johannes
Groß, Cornelius
Scheck, Anna
Pooseh, Shakoor
Mayer-Pelinski, René
Zimmermann, Ulrich S.
Smolka, Michael N.
Pilhatsch, Maximilian
author_facet Bernhardt, Nadine
Petzold, Johannes
Groß, Cornelius
Scheck, Anna
Pooseh, Shakoor
Mayer-Pelinski, René
Zimmermann, Ulrich S.
Smolka, Michael N.
Pilhatsch, Maximilian
author_sort Bernhardt, Nadine
collection PubMed
description AIM: Methamphetamine (MA) abuse and dependence are increasing worldwide and are commonly associated with cognitive deficits. Some studies indicate that such impairments can improve if users become abstinent, but overall results remain inconclusive. Hence, we have performed a longitudinal case-control study investigating key surrogates for attention and impulsive decision-making before and after treatment. METHODS: Thirty patients with MA dependence and 24 non–substance-abusing control participants were recruited. Groups were matched on age, sex and education. All subjects performed a baseline assessment to obtain neurocognitive measures of sustained attention and delay discounting. Patients subsequently participated in an MA-specific relapse prevention program including repeated monitoring of relapse status. After 3 months, participants of both groups were reevaluated for neurocognitive performance. RESULTS: At baseline, MA patients showed a significantly higher number of omissions compared to controls, indicative of lower sustained attention. Interestingly, we observed a steep decrease of omissions in MA patients to control-group level post treatment. On the other hand, MA patients discounted delayed rewards significantly stronger than controls, indicating a more impulsive choice behavior both before and after treatment. LIMITATION: The results should be interpreted with care because of the small sample and short follow-up period. CONCLUSION: Our data support earlier findings on partial recovery of cognitive deficits in MA patients. They also strengthen the indication for recently recommended psychotherapeutic interventions and may provide a behavioral monitoring tool to inform treatment progress.
format Online
Article
Text
id pubmed-7343893
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73438932020-07-25 Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study Bernhardt, Nadine Petzold, Johannes Groß, Cornelius Scheck, Anna Pooseh, Shakoor Mayer-Pelinski, René Zimmermann, Ulrich S. Smolka, Michael N. Pilhatsch, Maximilian Front Psychiatry Psychiatry AIM: Methamphetamine (MA) abuse and dependence are increasing worldwide and are commonly associated with cognitive deficits. Some studies indicate that such impairments can improve if users become abstinent, but overall results remain inconclusive. Hence, we have performed a longitudinal case-control study investigating key surrogates for attention and impulsive decision-making before and after treatment. METHODS: Thirty patients with MA dependence and 24 non–substance-abusing control participants were recruited. Groups were matched on age, sex and education. All subjects performed a baseline assessment to obtain neurocognitive measures of sustained attention and delay discounting. Patients subsequently participated in an MA-specific relapse prevention program including repeated monitoring of relapse status. After 3 months, participants of both groups were reevaluated for neurocognitive performance. RESULTS: At baseline, MA patients showed a significantly higher number of omissions compared to controls, indicative of lower sustained attention. Interestingly, we observed a steep decrease of omissions in MA patients to control-group level post treatment. On the other hand, MA patients discounted delayed rewards significantly stronger than controls, indicating a more impulsive choice behavior both before and after treatment. LIMITATION: The results should be interpreted with care because of the small sample and short follow-up period. CONCLUSION: Our data support earlier findings on partial recovery of cognitive deficits in MA patients. They also strengthen the indication for recently recommended psychotherapeutic interventions and may provide a behavioral monitoring tool to inform treatment progress. Frontiers Media S.A. 2020-07-02 /pmc/articles/PMC7343893/ /pubmed/32714215 http://dx.doi.org/10.3389/fpsyt.2020.00581 Text en Copyright © 2020 Bernhardt, Petzold, Groß, Scheck, Pooseh, Mayer-Pelinski, Zimmermann, Smolka and Pilhatsch http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Bernhardt, Nadine
Petzold, Johannes
Groß, Cornelius
Scheck, Anna
Pooseh, Shakoor
Mayer-Pelinski, René
Zimmermann, Ulrich S.
Smolka, Michael N.
Pilhatsch, Maximilian
Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study
title Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study
title_full Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study
title_fullStr Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study
title_full_unstemmed Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study
title_short Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study
title_sort neurocognitive dysfunctions and their therapeutic modulation in patients with methamphetamine dependence: a pilot study
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343893/
https://www.ncbi.nlm.nih.gov/pubmed/32714215
http://dx.doi.org/10.3389/fpsyt.2020.00581
work_keys_str_mv AT bernhardtnadine neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy
AT petzoldjohannes neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy
AT großcornelius neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy
AT scheckanna neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy
AT poosehshakoor neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy
AT mayerpelinskirene neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy
AT zimmermannulrichs neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy
AT smolkamichaeln neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy
AT pilhatschmaximilian neurocognitivedysfunctionsandtheirtherapeuticmodulationinpatientswithmethamphetaminedependenceapilotstudy